These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 11564050)
1. Therapeutic drug monitoring: antiarrhythmic drugs. Campbell TJ; Williams KM Br J Clin Pharmacol; 2001; 52 Suppl 1(Suppl 1):21S-34S. PubMed ID: 11564050 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring: antiarrhythmic drugs. Campbell TJ; Williams KM Br J Clin Pharmacol; 1998 Oct; 46(4):307-19. PubMed ID: 9803978 [TBL] [Abstract][Full Text] [Related]
3. Antiarrhythmic agents and proarrhythmia. Chaudhry GM; Haffajee CI Crit Care Med; 2000 Oct; 28(10 Suppl):N158-64. PubMed ID: 11055685 [TBL] [Abstract][Full Text] [Related]
4. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review. Snider M; Kalbfleisch S; Carnes CA Clin Ther; 2009 Jun; 31(6):1209-18. PubMed ID: 19695388 [TBL] [Abstract][Full Text] [Related]
5. [Therapeutic Drug Monitoring of Antiarrhythmic Drugs]. Takahashi N Rinsho Byori; 2016 Dec; 64(12):1390-1394. PubMed ID: 30653903 [TBL] [Abstract][Full Text] [Related]
6. A benefit-risk assessment of class III antiarrhythmic agents. Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126 [TBL] [Abstract][Full Text] [Related]
7. Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring. Takada M; Goto T; Kotake T; Saito M; Kawato N; Nakai M; Gunji T; Shibakawa M J Clin Pharm Ther; 2005 Feb; 30(1):5-12. PubMed ID: 15658999 [TBL] [Abstract][Full Text] [Related]
8. Class III antiarrhythmics in overdose. Presenting features and management principles. Leatham EW; Holt DW; McKenna WJ Drug Saf; 1993 Dec; 9(6):450-62. PubMed ID: 8129865 [TBL] [Abstract][Full Text] [Related]
9. [Current classification of anti-arrhythmia agents]. Weirich J; Wenzel W Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787 [TBL] [Abstract][Full Text] [Related]
11. Classification and mechanism of action of antiarrhythmic drugs. Scholz H Fundam Clin Pharmacol; 1994; 8(5):385-90. PubMed ID: 7875632 [TBL] [Abstract][Full Text] [Related]
12. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Nattel S; Singh BN Am J Cardiol; 1999 Nov; 84(9A):11R-19R. PubMed ID: 10568655 [TBL] [Abstract][Full Text] [Related]
14. Potentially significant drug interactions of class III antiarrhythmic drugs. Yamreudeewong W; DeBisschop M; Martin LG; Lower DL Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833 [TBL] [Abstract][Full Text] [Related]
15. [Principles for the classification of anti-arrhythmia agents in cardiac arrhythmias]. Ravens U Z Kardiol; 1992; 81 Suppl 4():119-25. PubMed ID: 1290288 [TBL] [Abstract][Full Text] [Related]
16. The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents. Follath F J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S41-3. PubMed ID: 1279308 [TBL] [Abstract][Full Text] [Related]